Expert Insights on the Use of Oral JAK Inhibitors for Atopic Dermatitis: Raising the Bar for Standard of Care

Christopher Bunick, MD, PhD, and Ruth Ann Vleugels, MD, MPD, MBA, discuss the method of action for Janus Kinase (JAK) inhibitors and the pathology of atopic dermatitis (AD).

Experts discuss a recent network meta-analysis comparing current monotherapies for atopic dermatitis (AD) and how this may change standards of care.

Ruth Ann Vleugels, MD, MPD, MBA, and Christopher Bunick, MD, PhD, provide their clinical experience with Janus Kinase (JAK) inhibitors and the importance of patient compliance with these agents.

Christopher Bunick, MD, PhD, introduces an integrated analysis of phase three studies analyzing the long-term safety of upadacitinib as treatment for atopic dermatitis (AD). He also highlights a burgeoning standard to assess the safety of treatment.

Christopher Bunick, MD, PhD, presents the results of the long-term four-year safety study of upadacitinib as treatment for atopic dermatitis (AD).

Christopher Bunick, MD, PhD, discusses the major study conclusions about the safety of upadacitinib as a treatment for atopic dermatitis.

Ruth Ann Vleugels, MD, MPD, MBA, provides important considerations for clinicians when reflecting upon the safety of oral Janus Kinase (JAK) inhibitors and traditional systemic immunosuppressants.

Christopher Bunick, MD, PhD, introduces the objectives and design of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Experts discuss the results of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Christopher Bunick, MD, PhD, discusses a novel tool to visualize key safety results of Janus kinase inhibitors in treating patients with atopic dermatitis.

Christopher Bunick, MD, PhD, and Ruth Ann Vleugels, MD, MPD, MBA, discuss the nuances of box warnings and how clinicians should assimilate these risk factors in the treatment of atopic dermatitis (AD).

Experts discuss the selectivity of Janus Kinase (JAK) inhibitors and considerations when selecting treatment for atopic dermatitis (AD).

Christopher Bunick, MD, PhD, presents the conclusions and major take-aways of the study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Experts discuss how new data are evolving standards of care for atopic dermatitis (AD) in terms of safety and redefining response to therapy.

Experts offer their clinical advice on when and how to transition patients from a biologic or immunosuppressive agent to a Janus Kinase (JAK) inhibitor.

Christopher Bunick, MD, PhD, discusses how a patient’s atopic dermatitis (AD) endotype may alter treatment approaches in the future.

Experts conclude their discussion highlighting key takeaways and considerations when using Janus Kinase (JAK) inhibitors as treatment for atopic dermatitis (AD).